Proactive Investors - Run By Investors For Investors

Boston Scientific rises as preliminary 4Q sales figures match consensus estimate

For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion
A surgeon putting on gloves
For all of 2018, Boston Scientific reported a 8.6% gain in preliminary sales

Boston Scientific Corp (NYSE:BSX) advanced Tuesday after reporting preliminary fourth-quarter sales figures that were in line with the consensus estimate.

The Marlborough, Massachusetts-based medical products company said preliminary sales increased 6.3% on a reported based during the fourth quarter to $2.56 billion. That matched the average estimate of analysts.

READ: Johnson & Johnson third-quarter results beat estimates; raises guidance for 2018

Shares of Boston Scientific rose $0.47, or 1.4%, to $34.89 in New York Stock Exchange trading.
 
For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion.

Highlights included a 10.9% gain in its urology and pelvic health segment and 6.4% growth in its cardiovascular business.

Contact Dennis Fitzgerald at [email protected]

View full BSX profile View Profile

Boston Scientific Timeline

Related Articles

Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
glasshouse
January 08 2019
Its plans to become a first-mover seed-to-consumer business here in the UK, following the model pioneered in Canada
Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use